Search Results

Almirall, S.A., a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

etherna, a leading mRNA/LNP technologies company, announced that Bernard Sagaert has been confirmed-as Chief Executive Officer.

etherna announced today that Steffen Helmling, PhD has been appointed Chief Business Officer.

Money is now flowing into promising platforms for prostate cancer from AdvanCell, mRNA therapeutics from eTheRNA, hepatitis from Bluejay and more.

eTheRNA immunotherapies NV, an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium.

Theralase® Technologies Inc. is pleased to announce that in preclinical research, it’s lead drug formulation, Rutherrin®, has demonstrated an ability to increase the efficacy of immunotherapy.

eTheRNA immunotherapies NV (‘eTheRNA’), an mRNA technology discovery and development company with a full platform of integrated capabilities, today announced that it will host a key opinion leader (KOL) webinar on mRNA-lipid nanoparticles (LNP) for cancer immunotherapy on Wednesday, March 2, 2022 at 10am ET / 3pm GMT / 4pm CET.

“Currently More Than 180 Oncolytic Virus Immunotherapies Are In Clinical Trials”